JEROME NWOKIKE: Open Payments
NPI 1346225794 · NORTH LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$535 in 21 payments from 12 companies in 2025. Trend: 2023 $1,276 · 2024 $464 · 2025 $535
Food & beverage: $535
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 2 | $68 |
| Abbott Laboratories | 2 | $64 |
| Novo Nordisk Inc | 3 | $62 |
| E.R. Squibb & Sons, L.L.C. | 3 | $60 |
| Janssen Pharmaceuticals, Inc | 2 | $57 |
| Dexcom, Inc. | 2 | $54 |
| Mannkind Corporation | 2 | $46 |
| Averitas Pharma Inc. | 1 | $35 |
| ABBVIE INC. | 1 | $27 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
Products named: INGREZZA, FREESTYLE LIBRE 3, Ozempic, COBENFY, Dexcom G6 Transmitter, AFREZZA, QUTENZA, SPRAVATO.
Industry payments across NV — which companies pay providers there.
